$0.66
▲ +6.4% Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
Invivyd Gets FDA Notice of Pemgarda COVID-19 Emergency Use Authorization Termination
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
Overview
52-week range
$0.48
$3.07
7% of range
Avg surprise (last 3)
-170.8%
Avg reaction (last 2)
-18.4%
0% positive
Latest IV / EM
225%
EM ±53.2% · $1 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.13 | $-0.08 | -62.5% | +7.1% | -21.1% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.06 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.12 | $-0.04 | -200.0% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.14 | $-0.04 | -250.0% | — | -15.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.51 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.40 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.38 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.36 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.46 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.15 | -$0.12 | -25.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | — | $13M | $12M | $11M | — | $9M | $2M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-43M | — | $-11M | $-15M | $-17M | — | $-62M | $-49M |
| Net income | $-41M | — | $-10M | $-15M | $-16M | — | $-61M | $-47M |
| EPS (diluted) | $-0.13 | — | $-0.06 | $-0.12 | $-0.14 | — | $-0.51 | $-0.40 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $184M | $227M | $85M | $35M | $48M | $69M | $107M | $148M |
| Inventory | — | — | $25M | $25M | $25M | $26M | $27M | $5M |
| Total current assets | $205M | $247M | $110M | $59M | $76M | $101M | $151M | $173M |
| Total assets | $242M | $277M | $139M | $89M | $104M | $130M | $162M | $177M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $39M | $35M | $46M | $46M | $50M | $62M | $79M | $37M |
| Total equity | $203M | $242M | $93M | $43M | $54M | $68M | $83M | $141M |